Feb 16 (Reuters) - Astrazeneca Plc AZN.L :
* Partner Valeant Pharmaceuticals (NYSE:VRX) announced that US FDA has approved Siliq (Brodalumab) injection for treatment of adult patients with moderate-to-severe plaque psoriasis
* Through a collaboration agreement, astrazeneca granted valeant exclusive license to develop and commercialise siliq globally, except in japan and certain other asian countries
* Under terms of agreement, Astrazeneca will receive a milestone payment of $130 million from valeant at first regulatory approval
* This milestone will be recorded in Astrazeneca financial statements as externalisation revenue
* Following approval, Astrazeneca and Valeant will share profits from sale of siliq in US market. Source text for Eikon: ID:nRSP0888Xa Further company coverage: AZN.L
(Bengaluru Newsroom: +91 80 6749 1136)